Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Business Exposures
Activism
Animal Testing
Artificial Intelligence
Boeing 737
Brexit
Cannabis
Censorship
Climate
Coal
COVID-19
Criminal
Death
Debt Markets
Derivatives
Diversity
Economy
Electric Vehicles
Electricity Generation
Ethanol
Financial
Firearms
Fossil Fuels
Glyphosate
Harassement
Immigration
Information Security
Intellectual Property
Interest Rates
Labor
Layoff
Lead
Legal
Palm Oil
Pension
Political
Product Safety
Regulatory
Religion
Securities Market
Supply Chain
Tariff
Textiles
US Equities
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
99
100
Next >
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)
April 16, 2024
Via
TheNewswire.com
Exposures
Product Safety
Tickers
MRZM
QLGN
Successful Development of pH Neutral Ketamine, Potentially Enabling Both Intravenous and Subcutaneous Use; Trials Progressing for Suicide Drug Treatment After Strong Q4 Results: NRXP
April 15, 2024
Via
Get News
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
NRXP
Navigating Age Requirements and Suitability for LASIK Surgery in California with Lucent Vision
April 15, 2024
Via
Press Advantage
Exposures
Product Safety
Why Is Penny Stock Soligenix Trading Higher On Monday?
April 15, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
SNGX
The Advantages of Using a Dynamic Checkweigher in The Production Line
April 15, 2024
Via
AB Newswire
Topics
Product Recall
Exposures
Legal
Product Safety
Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?
April 15, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
NMRA
INMD DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD
April 15, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
INMD
INMD DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD
April 15, 2024
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
INMD
INMD FINAL DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD
April 14, 2024
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
INMD
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE
April 14, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
BLUE
INMD FINAL DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD
April 14, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
INMD
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE
April 14, 2024
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
BLUE
INMD DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD
April 13, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
INMD
INMD DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD
April 13, 2024
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
INMD
ROSEN, LEADING INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE
April 13, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
BLUE
ROSEN, LEADING INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE
April 13, 2024
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
BLUE
ROSEN, NATIONAL TRIAL COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE
April 12, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
BLUE
INMD DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD
April 12, 2024
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
INMD
ROSEN, NATIONAL TRIAL COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE
April 12, 2024
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
BLUE
INMD DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD
April 12, 2024
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Tickers
INMD
Analyst Reacts To FDA Commish Comments: Medical And Recreational Cannabis Could Have Separate Regulations
April 12, 2024
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Product Safety
Game-Changing Tumor Freezing Technology Has The Potential To Offer Women First-Ever Minimally Invasive Alternative To Breast Lumpectomy Surgery
April 12, 2024
Via
News Direct
Exposures
Product Safety
Tickers
ICCM
Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies
April 12, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
PXMD
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
April 12, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
AZN
LLY
NVO
SNY
FDA Commissioner To House Committee: 'There's No Reason For DEA To Delay' Cannabis Rescheduling
April 12, 2024
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Product Safety
IRA Capital Acquires 237,000 Square-Foot Life Science/R&D Campus in Columbus
April 11, 2024
Via
Newsfile
Exposures
Product Safety
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R) in 2024
April 11, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
CLNN
What's Going On With Candel Therapeutics Stock?
April 11, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
CADL
Utah attempts to legalize placenta cell therapy
April 11, 2024
Via
PRLog
Topics
Law Enforcement
Lawsuit
Exposures
Financial
Legal
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Presents New Data from NGC-Cap Phase 1b Trial at AACR Annual Meeting
April 11, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
PCSA
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.